KB CV 001
Alternative Names: KB-CV-001Latest Information Update: 28 Sep 2020
At a glance
- Originator Krisani Biosciences
- Class Antihyperglycaemics; Eicosanoids; Omega 3 fatty acids; Small molecules
- Mechanism of Action Arachidonic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertriglyceridaemia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Hypertriglyceridaemia in India
- 12 Aug 2016 Preclinical trials in Hypertriglyceridaemia in India (unspecified route)